An isolated monoclonal antibody or antigen-binding fragment thereof that has an anti-angiogenic effect, but does not inhibit endothelial cell proliferation and that: binds to both human fibronectin and human fibrinogen and is any one of the antibodies produced by the hybridoma deposited at the American Type Culture Collection (ATCC) and designated as PTA-120972, PTA-120970, or PTA-120971; or binds to both human fibronectin and human fibrinogen and comprises three heavy chain CDRs and three light chain CDRs, wherein: (i) the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO:20, (ii) the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO:22, (iii) the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO:24, (iv) the light chain CDR1 comprises the amino acid sequence of SEQ ID NO:28, (v) the light chain CDR2 comprises the amino acid sequence of SEQ ID NO:30, and (vi) the light chain CDR3 comprises the amino acid sequence of SEQ ID NO:32; or binds to both human fibronectin and human fibrinogen and comprises three heavy chain CDRs and three light chain CDRs, wherein: (i) the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO:4, (ii) the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO:6, (iii) the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO:8, (iv) the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 12, (v) the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 14, and (vi) the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 16. binds to both human fibronectin and human fibrinogen and is any one of the antibodies produced by the hybridoma deposited at the American Type Culture Collection (ATCC) and designated as PTA-120972, PTA-120970, or PTA-120971; or binds to both human fibronectin and human fibrinogen and comprises three heavy chain CDRs and three light chain CDRs, wherein: (i) the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO:20, (ii) the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO:22, (iii) the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO:24, (iv) the light chain CDR1 comprises the amino acid sequence of SEQ ID NO:28, (v) the light chain CDR2 comprises the amino acid sequence of SEQ ID NO:30, and (vi) the light chain CDR3 comprises the amino acid sequence of SEQ ID NO:32; or (i) the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO:20, (ii) the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO:22, (iii) the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO:24, (iv) the light chain CDR1 comprises the amino acid sequence of SEQ ID NO:28, (v) the light chain CDR2 comprises the amino acid sequence of SEQ ID NO:30, and (vi) the light chain CDR3 comprises the amino acid sequence of SEQ ID NO:32; or binds to both human fibronectin and human fibrinogen and comprises three heavy chain CDRs and three light chain CDRs, wherein: (i) the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO:4, (ii) the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO:6, (iii) the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO:8, (iv) the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 12, (v) the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 14, and (vi) the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 16. (i) the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO:4, (ii) the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO:6, (iii) the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO:8, (iv) the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 12, (v) the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 14, and (vi) the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 16.